Dr. Qian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 E Jefferson St
Ste A1
Seattle, WA 98122Phone+1 206-320-2200Fax+1 206-320-2560
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2007 - 2010
SSM St Mary's Hospital-St LouisInternship, Internal Medicine, 2006 - 2007
Shanghai Jiao Tong University School of MedicineClass of 1993
Certifications & Licensure
WA State Medical License 2012 - 2025
MO State Medical License Active through 2013- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Vitamin D Supplementation in Multiple Sclerosis Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- 101 citationsSafety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, Keith R Edwards, Peter A. Calabresi
The Lancet. Neurology. 2019-07-05 - 23 citationsIron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton FractionVasily L. Yarnykh, Elena Krutenkova, G. Aitmagambetova, Pavle Repovic, Angeli Mayadev
AJNR. American Journal of Neuroradiology. 2018-02-08 - 16 citationsHigh-dose vitamin Dsupplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial.Sandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, Susan A Emrich, Christina J Azevedo
Eclinicalmedicine. 2023-05-01
Press Mentions
ACTRIMS 2023: Most on Briumvi Show No MS Activity After 6 MonthsMarch 2nd, 2023- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (Ublituximab) in Multiple Sclerosis to Be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumFebruary 14th, 2023
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
